Aardvark Therapeutics(AARD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AARD Aardvark Therapeutics

休市中 04-10 16:00:00 EDT

3.94

+0.04

+1.03%

盘后3.97

+0.03+0.76%

17:51 EDT

最高4.02	最低3.87	成交量11.50万
今开3.92	昨收3.90	日振幅3.73%
总市值8,549万	流通市值2,320万	总股本2,170万
成交额45.27万	换手率1.95%	流通股本588.80万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AARD","market":"US","secType":"STK","nameCN":"Aardvark Therapeutics","latestPrice":3.94,"timestamp":1775851200000,"preClose":3.9,"halted":0,"volume":114996,"hourTrading":{"tag":"盘后","latestPrice":3.97,"preClose":3.94,"latestTime":"17:51 EDT","volume":14036,"amount":56255.76,"timestamp":1775857868143,"change":0.03,"changeRate":0.007614,"amplitude":0.073604},"delay":0,"changeRate":0.010256410256410265,"floatShares":5888000,"shares":21696893,"eps":-2.6398466,"marketStatus":"休市中","change":0.04,"latestTime":"04-10 16:00:00 EDT","open":3.92,"high":4.015405,"low":3.87,"amount":452703.77573399997,"amplitude":0.037283,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.6398466,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1776067200000},"marketStatusCode":7,"adr":0,"listingDate":1739509200000,"exchange":"NASDAQ","adjPreClose":3.9,"postHourTrading":{"tag":"盘后","latestPrice":3.97,"preClose":3.94,"latestTime":"17:51 EDT","volume":14036,"amount":56255.76,"timestamp":1775857868143,"change":0.03,"changeRate":0.007614,"amplitude":0.073604},"volumeRatio":0.7381738884299427,"impliedVol":2.1499,"impliedVolPercentile":0.8545},"requestUrl":"/m/hq/s/AARD","defaultTab":"news","newsList":[{"id":"1132251302","title":"Aardvark Therapeutics与Piper Sandler签订股权分销协议，于2026年3月23日提交SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1132251302","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132251302?lang=zh_cn&edition=full","pubTime":"2026-03-24 18:11","pubTimestamp":1774347083,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc. 已与Piper Sandler公司正式签署了一项股权分销协议。该协议的具体条款于2026年3月23日通过美国证券交易委员会（SEC）的文件对外公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146815608","title":"Aardvark Therapeutics暂停针对PWS的Ard-101三期HERO及OLE试验；最新指引预计2026年第二季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1146815608","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146815608?lang=zh_cn&edition=full","pubTime":"2026-03-24 04:23","pubTimestamp":1774297410,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics公司宣布，已暂停其候选药物Ard-101用于治疗普瑞德-威利综合征（PWS）的三期HERO临床试验及开放标签扩展（OLE）研究。\n公司表示，预计将在2026年第二季度提供关于该研发项目下一步计划的进一步指导。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125745058","title":"Aardvark Therapeutics暂停Ard-201肥胖症项目，包括力量与体能试验；进一步指引预计2026年第二季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1125745058","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125745058?lang=zh_cn&edition=full","pubTime":"2026-03-24 04:21","pubTimestamp":1774297278,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics已决定暂停其Ard-201肥胖症治疗项目的研发进程，该项目原计划包含针对患者力量与体能改善的临床试验。公司表示，关于该项目的后续发展方向及详细计划，预计将在2026年第二季度提供进一步的明确指引。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103365650","title":"RBC下调Aardvark Therapeutics评级至行业平配，目标价大幅砍至6美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1103365650","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103365650?lang=zh_cn&edition=full","pubTime":"2026-03-02 13:52","pubTimestamp":1772430778,"startTime":"0","endTime":"0","summary":"加拿大皇家银行（RBC）宣布，将Aardvark Therapeutics的股票评级从“跑赢大盘”下调至“行业平配”，同时将其目标价从18美元大幅削减至6美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162306225","title":"Aardvark Therapeutics：因超出目标剂量出现可逆性心脏观察结果，暂停Hero及开放标签扩展试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1162306225","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162306225?lang=zh_cn&edition=full","pubTime":"2026-02-28 05:08","pubTimestamp":1772226491,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics宣布，在发现高于目标剂量出现可逆性心脏相关观察结果后，已决定暂停其Hero试验以及开放标签扩展研究。公司强调，该心脏异常现象在停药后具有可逆性，目前正与监管机构密切沟通，进一步评估相关数据以确定后续研究方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177858931","title":"Aardvark Therapeutics：基于超目标治疗剂量下可逆心脏观察结果作出决策","url":"https://stock-news.laohu8.com/highlight/detail?id=1177858931","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177858931?lang=zh_cn&edition=full","pubTime":"2026-02-28 05:08","pubTimestamp":1772226490,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics公司宣布，其决策依据是在高于目标治疗剂量下发现的可逆性心脏观察结果。这一发现对药物安全性评估具有关键意义，表明在特定剂量范围内出现的心脏影响是可逆的，为公司后续临床开发路径提供了重要参考。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174773215","title":"Aardvark Therapeutics 成立美国子公司 推进皮肤病产品管线发展；任命 Bryan Jones 为首席执行官","url":"https://stock-news.laohu8.com/highlight/detail?id=1174773215","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174773215?lang=zh_cn&edition=full","pubTime":"2026-02-12 21:06","pubTimestamp":1770901613,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics 宣布成立新的美国子公司，旨在支持其皮肤病产品管线的开发进程。公司同时宣布，任命 Bryan Jones 担任该子公司的首席执行官。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193243066","title":"Aardvark Therapeutics宣布向FDA提交并获IRB批准其主打候选药物ARD-101的修订试验方案，扩大普瑞德-威利综合征III期研究受试者资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1193243066","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193243066?lang=zh_cn&edition=full","pubTime":"2026-02-10 21:05","pubTimestamp":1770728724,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics今日宣布，已向美国食品药品监督管理局（FDA）提交了其主打候选药物ARD-101的修订临床试验方案，并已获得机构审查委员会（IRB）的批准。此项修订旨在扩大针对普瑞德-威利综合征（PWS）的III期临床研究的受试者资格范围。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119474932","title":"Aardvark Therapeutics Inc - 加拿大和英国的临床试验地点已获得注册许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1119474932","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119474932?lang=zh_cn&edition=full","pubTime":"2025-12-11 05:24","pubTimestamp":1765401846,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc - 加拿大和英国的临床试验地点已获得注册许可","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150804035","title":"Aardvark Therapeutics在澳大利亚进行的英雄三期试验中宣布首位患者接受治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1150804035","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150804035?lang=zh_cn&edition=full","pubTime":"2025-12-11 05:05","pubTimestamp":1765400713,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics在澳大利亚进行的英雄三期试验中宣布首位患者接受治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194886481","title":"Aardvark Therapeutics宣布FDA就扩大针对普拉德-威利综合征的三期Hero试验人群的协议修订达成一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1194886481","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194886481?lang=zh_cn&edition=full","pubTime":"2025-10-08 20:02","pubTimestamp":1759924977,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics宣布FDA就扩大针对普拉德-威利综合征的三期Hero试验人群的协议修订达成一致","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518226139","title":"Aardvark Therapeutics(AARD.US)获B of A Securities首次覆盖，给予买入评级, 目标价22.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518226139","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518226139?lang=zh_cn&edition=full","pubTime":"2025-03-10 20:41","pubTimestamp":1741610495,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics(AARD.US)获B of A Securities首次覆盖，给予买入评级, 目标价22.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/10204148634837.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AARD","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://aardvarktherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0837},{"period":"1month","weight":-0.2423},{"period":"3month","weight":-0.7239},{"period":"6month","weight":-0.7577},{"period":"1year","weight":-0.4387},{"period":"ytd","weight":-0.6998}],"compareEarnings":[{"period":"1week","weight":0.036},{"period":"1month","weight":0.0046},{"period":"3month","weight":-0.021},{"period":"6month","weight":0.0405},{"period":"1year","weight":0.2952},{"period":"ytd","weight":-0.0036}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Aardvark Therapeutics, Inc.于2017年5月17日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司，专注于开发新颖的小分子疗法，以激活用于治疗代谢疾病的先天稳态途径。该公司瞄准了与缓解饥饿相关的生物途径，该公司认为这些途径有可能为患者带来变革性的结果。该公司已将精力集中在开发选择性化合物上，针对与饥饿相关的情况开发苦味受体。","exchange":"NASDAQ","name":"Aardvark Therapeutics","nameEN":"Aardvark Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aardvark Therapeutics(AARD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Aardvark Therapeutics(AARD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Aardvark Therapeutics,AARD,Aardvark Therapeutics股票,Aardvark Therapeutics股票老虎,Aardvark Therapeutics股票老虎国际,Aardvark Therapeutics行情,Aardvark Therapeutics股票行情,Aardvark Therapeutics股价,Aardvark Therapeutics股市,Aardvark Therapeutics股票价格,Aardvark Therapeutics股票交易,Aardvark Therapeutics股票购买,Aardvark Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aardvark Therapeutics(AARD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Aardvark Therapeutics(AARD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}